Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 1,7411,760 of 20,252 grants

Completed OTHER RESEARCH-RELATED
Advancing the Science of Cancer in Latinos 2024
NATIONAL CANCER INSTITUTE University of Texas Hlth Science Center United States 2024 – 2024

Project Summary/Abstract The Institute for Health Promotion Research (IHPR) and the Mays Cancer Center, an NCI-designated cancer center at UT Health San Antonio, partner closely to...

$100K
USD
Completed NON-SBIR/STTR RPGS
Mitochondrial bioenergetics and colorectal cancer
NATIONAL CANCER INSTITUTE East Carolina University United States 2024 – 2024

ABSTRACT Relative to matched normal tissue, recent large scale sequencing efforts indicate that colorectal cancer (CRC) tumors are specifically enriched in loss of function mutatio...

$951.2K
USD
Active NON-SBIR/STTR RPGS
Mitochondrial bioenergetics and colorectal cancer
NATIONAL CANCER INSTITUTE Wake Forest University Health Sciences United States 2024 – 2029

ABSTRACT Relative to matched normal tissue, recent large scale sequencing efforts indicate that colorectal cancer (CRC) tumors are specifically enriched in loss of function mutatio...

$4.74M
USD
Completed NON-SBIR/STTR RPGS
Identifying non-cardiotoxic drug combinations for patients with relapsed sarcoma
NATIONAL CANCER INSTITUTE Seattle Children'S Hospital United States 2024 – 2026

Summary Standard-of-care treatments for most sarcomas and other childhood cancers include high-doses of anthracyclines, in particular doxorubicin (DOXO). DOXO causes irreparable da...

$2.76M
USD
Completed NON-SBIR/STTR RPGS
Expanding the targetable landscape in cancer with serine-targeting covalent ligands
NATIONAL CANCER INSTITUTE University of California Berkeley United States 2024 – 2026

Project Summary Targeted covalent inhibitors have empowered the potent and selective targeting of driver oncogenes in cancer. Between 2011 and 2021, 16 new covalent drugs (12 with...

$2.25M
USD
Active NON-SBIR/STTR RPGS
Selective targeting of TAF1 function in acute myeloid leukemia
NATIONAL CANCER INSTITUTE H. Lee Moffitt Cancer Ctr & Res Inst United States 2024 – 2029

PROJECT SUMMARY Although dysregulated gene transcription is a major contributing factor in cancer, the development of drugs interfering with general transcription remains a challen...

$6.36M
USD
Completed SBIR/STTR CONTRACTS
2024 SBIR CONCEPT CLEARANCE AWARD
NATIONAL CANCER INSTITUTE Unknown United States 2024 – 2025

Positron emission tomography (PET), a sensitive functional imaging technique, holds potential for diagnosing and monitoring medical conditions. Its use in pediatric oncology is hin...

$3.53M
USD
Active NON-SBIR/STTR RPGS
Developing biomarkers of response for a new therapy in ovarian cancer
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2024 – 2028

PROJECT SUMMARY Clear cell ovarian cancer (CCOC) is one of the most challenging subtypes of ovarian cancer (OVCA) to treat, as it is resistant to standard chemotherapy and is assoc...

$6.93M
USD
Completed NON-SBIR/STTR RPGS
Immunotherapy of prostate cancer using an anti-CD6 monoclonal antibody
NATIONAL CANCER INSTITUTE University of Michigan At Ann Arbor United States 2024 – 2026

PROJECT SUMMARY/ABSTRACT Limitations of checkpoint inhibitor cancer treatment include precipitation of autoimmunity and resistance to immunotherapy. For some cancers, notably prost...

$1.82M
USD
Active OTHER RESEARCH-RELATED
Cancer Screening Research Network - North Carolina Hub (CSRN-NC HUB)
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2024 – 2027

PROJECT SUMMARY/ABSTRACT Although evidence-based cancer screening protocols exist for several common cancer types, an estimated 70% of cancer deaths are due to cancers for which no...

$8.76M
USD
Active OTHER RESEARCH-RELATED
Multi-Ethnic Multi-Cancer Early Detection and Screening (MED SCREEN) Study
NATIONAL CANCER INSTITUTE Kaiser Foundation Research Institute United States 2024 – 2027

Project Summary Multi-cancer detection (MCD) tests, which evaluate cell-free DNA and other biological components with a single blood draw, are a new frontier in cancer screening, p...

$8.58M
USD
Completed SBIR/STTR CONTRACTS
CONCEPT SBIR - T-CELL RECEPTORS FOR TREATING PEDIATRIC ACUTE MYELOID LEUKEMIA
NATIONAL CANCER INSTITUTE Vcreate, Inc United States 2024 – 2025

More than 30% of children diagnosed with acute myeloid leukemia (AML) relapse after initial treatment, creating an urgent need for new treatment options.T-cell receptor (TCR) based...

$3.55M
USD
Completed SBIR/STTR CONTRACTS
Phase I Therapeutic Award - Developing Split, Conditionally Active Peptidomimetics of IL-12 For the Treatment of Rare Pediatric DIPG
NATIONAL CANCER INSTITUTE Utter Therapeutics Inc United States 2024 – 2025

Diffuse intrinsic pontine glioma (DIPG) is a rare, universally fatal childhood brainstem tumor, striking about 150-300 children in the US with a median survival of only 9-11 months...

$3M
USD
Completed SBIR/STTR CONTRACTS
SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS
NATIONAL CANCER INSTITUTE Atux Iskay Group Llc United States 2024 – 2025

The five year survival of children with refractory or relapsed neuroblastoma (NBL), often with MYCN amplified tumors, is only about 10%, and the outcome for this subset of patients...

$3.55M
USD
Completed SBIR/STTR CONTRACTS
SBIR CONCEPT AWARD "THERAPEUTICS" - TARGETED DELIVERY OF FERROPTOSIS INDUCERS FOR TREATMENT OF ADRENOCORTICAL CARCINOMA
NATIONAL CANCER INSTITUTE Qana Therapeutics Inc United States 2024 – 2025

This proposal seeks to develop a novel therapeutic approach for recurrent or metastatic adrenocortical carcinoma (ACC), a rare and aggressive malignancy of the adrenal cortex. The...

$3.55M
USD
Completed SBIR/STTR CONTRACTS
Ultrasound-based Diagnosis and Monitoring of Neutropenic Enterocolitis in Children with Acute Lymphoblastic Leukemia
NATIONAL CANCER INSTITUTE Novateur Research Solutions, Llc United States 2024 – 2025

Acute lymphocytic leukemia, a blood cancer, is most common among children under five and is treated with chemotherapy.Neutropenic enterocolitis (NEC) is a life-threatening complica...

$3.55M
USD
Completed SBIR/STTR CONTRACTS
SBIR FY24 CONCEPT AWARD-DRUG REPURPOSING FOR RARE CANCERS USING A LARGE-SCALE, HIGH-QUALITY BIOMEDICAL KNOWLEDGE GRAPH
NATIONAL CANCER INSTITUTE Insilicom, Llc United States 2024 – 2025

This proposal aims to advance drug repurposing for rare cancers by utilizing cutting-edge computational approaches. The long-term objectives are to discover effective treatments fo...

$3.55M
USD
Completed SBIR/STTR CONTRACTS
2024 SBIR CONCEPT CLEARANCE AWARD
NATIONAL CANCER INSTITUTE Focal Medical, Inc United States 2024 – 2025

Oral cancer remains a life-threatening disease with 11,580 deaths in the US each year. Surgery provides the best chance of survival and is the preferred treatment option for oral c...

$2.98M
USD
Completed NON-SBIR/STTR RPGS
Exploiting Lineage-Specific Dependencies in Solid Tumors: Using Transcription Factors to Drive Therapeutic Effect In Situ
NATIONAL CANCER INSTITUTE Medical University of South Carolina United States 2024 – 2026

Many cancers exhibit aberrant overexpression of developmental lineage-specific transcription factors.In this project we investigate the potential of exploiting oncogenic overexpres...

$2.12M
USD
Active NON-SBIR/STTR RPGS
Aberrant V(D)J recombination in B cells initiates lymphoid malignancy
NATIONAL CANCER INSTITUTE University of California-Irvine United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Chromosomal translocations occur in nearly all human lymphoid neoplasms, many the result of aberrant repair of DNA double-stand breaks (DSBs) generated in...

$3.43M
USD